NewLimit, founded by Coinbase CEO Brian Armstrong and others, has raised $130 million in Series B funding to advance its goal of extending healthy lifespans. The company is focusing on developing treatments that rejuvenate aged cells, particularly liver cells. With early lab experiments showing promising results, NewLimit has discovered prototype medicines that help restore youthful functions. Although human trials are still a couple of years away, the startup plans to utilize AI to enhance drug development using a simulation method for improved efficiency in testing and research.
NewLimit, a startup focused on extending healthy lifespans by genetically programming cells, raised a $130 million Series B funding, aiming at developing anti-aging treatments.
NewLimit has made notable strides in rejuvenating aged liver cells, making them behave like younger cells, despite being a few years away from human trials.
The company utilizes an AI model to simulate experiments, enabling it to focus resources on the most promising anti-aging drug candidates identified through data-driven methods.
Bryers mentions that they discovered three prototype medicines that successfully reprogram liver cells to regain functions akin to those of younger cells.
Collection
[
|
...
]